Drugs / LEO 158968
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06444867 | Jan → Sep 2025 | arthritic joint disease, gout | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05682352 | Feb 2023 → May 2024 | — | LEO Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEO 158968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05682352 ↗ |
| Route | Intravenous | “via an intravenous (IV) infusion or subcutaneous (SC) injection” NCT05682352 ↗ |
| Route | Subcutaneous | “via an intravenous (IV) infusion or subcutaneous (SC) injection” NCT05682352 ↗ |